Savara Inc (NASDAQ:SVRA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Savara Inc (NASDAQ:SVRA) have received an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.83.

SVRA has been the topic of a number of research analyst reports. Wells Fargo & Company assumed coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. grew its stake in shares of Savara by 6.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company’s stock worth $26,587,000 after acquiring an additional 502,994 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Savara by 24.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company’s stock valued at $482,000 after purchasing an additional 31,168 shares in the last quarter. Woodline Partners LP raised its holdings in Savara by 16.6% in the fourth quarter. Woodline Partners LP now owns 2,686,938 shares of the company’s stock worth $8,249,000 after buying an additional 381,743 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after buying an additional 2,685,000 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of Savara by 178.1% in the fourth quarter. Squarepoint Ops LLC now owns 122,635 shares of the company’s stock worth $376,000 after buying an additional 78,540 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Trading Down 1.4 %

Shares of SVRA opened at $2.82 on Monday. Savara has a 1-year low of $2.26 and a 1-year high of $5.34. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm’s 50-day moving average price is $2.73 and its 200-day moving average price is $3.30. The firm has a market capitalization of $483.97 million, a price-to-earnings ratio of -6.56 and a beta of 0.60.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.